Nicotine Dependence Treatment in Psychiatric Comorbidity

精神共病的尼古丁依赖治疗

• 批准号: 6515854
• 负责人: JILL M WILLIAMS
• 金额: $ 16.13万
• 依托单位: UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6515854
• 关键词: behavior therapy; behavioral /social science research tag; blood chemistry; clinical trials; comorbidity; craving; drug abuse chemotherapy; drug administration rate /duration; drug withdrawal; human subject; human therapy evaluation; immunologic assay /test; inhalation drug abuse; interview; longitudinal human study; nicotine replacement; outcomes research; patient oriented research; questionnaires; schizophrenia; smoking; smoking cessation; social psychology; tobacco abuse prevention; urinalysis

Nicotine dependence is very common among psychiatric patients and impacts clinical course, medication levels, and physical health of smokers. Unfortunately, there is a paucity of research for this subgroup of smokers and minimal treatment studies. The goals of this NIDA Mentored Patient-Oriented Research Career Development Award (K23) are to become an independent clinical researcher and create a program of research in the area of nicotine dependence and psychiatric comorbidity. This includes further training in Epidemiology and Quantitative Methods including research methodology, biostatistics and biocomputing, experiment design, process research and comorbidity issues. The UMDNJ-Robert Wood Johnson Medical School and the Rutgers Center for Alcohol Studies provide an excellent environment for developing research investigators. The primary mentor, Douglas Ziedonis, had extensive research experience, a NIDA Career Award, and is a leading psychiatrist studying nicotine dependence among individuals with schizophrenia. The research plan includes two studies. 1: Pharmacotherapy for Nicotine Dependence Among Psychiatric Patients. During a six-month study, schizophrenic smokers will be recruited into a double blind study comparing multiple doses of nicotine replacement pact .schizophrenics are believed to be more heavily dependent on nicotine, therefore, higher dose strategies and longer duration of treatment may yield greater quit rates. Study 2: Psychosocial Treatment for Nicotine Dependence Among Psychiatric Patients. Using NIDA stage a Behavioral Therapy approach, the specific aims of this study are to develop patient and clinical manuals, create adherence and rating scales and formalize a training program for clinicians and conduct a pilot study. Schizophrenics have unique disabilities in processing information and interpersonal communications that require specific and tailored therapies. Techniques from dual diagnosis treatment can be adapted for treating nicotine dependence and include aspects of social skills training, motivational enhancement therapy and relapse prevention.

尼古丁依赖性在精神病患者中非常普遍，会影响吸烟者的临床病程，药物水平和身体健康。不幸的是，对于吸烟者和最少的治疗研究，研究很少。 NIDA指导的以患者为导向的研究职业发展奖（K23）的目标是成为独立的临床研究人员，并在尼古丁依赖和精神病合并症领域创建研究计划。这包括进一步的流行病学和定量方法培训，包括研究方法，生物统计学和生物计算，实验设计，过程研究和合并症问题。 Umdnj-Robert Wood Johnson医学院和Rutgers酒精研究中心为开发研究人员提供了一个绝佳的环境。主要的导师道格拉斯·齐底尼斯（Douglas Ziedonis）拥有广泛的研究经验，是NIDA职业奖，并且是研究精神分裂症患者尼古丁依赖性的领先精神病医生。研究计划包括两项研究。 1：精神病患者尼古丁依赖性的药物疗法。在一项为期六个月的研究中，将精神分裂症患者将被招募到一项双盲研究中，比较多种尼古丁替代条约。据信，雪schizizophrenics更加严重地依赖于尼古丁，因此，较高的剂量策略和更长的治疗持续时间可能会产生更高的戒烟率。研究2：精神病患者中尼古丁依赖性的社会心理治疗。使用NIDA阶段A行为疗法方法，本研究的具体目的是开发患者和临床手册，创建依从性和评级量表，并为临床医生进行培训计划并进行试点研究。精神分裂症患者在处理信息和人际交往方面具有独特的残疾，需要特定和量身定制的疗法。双重诊断治疗的技术可以适应治疗尼古丁依赖性，包括社交技能培训，动机增强疗法和预防复发的方面。